Affiliation:
1. Department of Cardiology University Medical Centre Groningen, University of Groningen Groningen The Netherlands
Abstract
AbstractThe emergence of personalized medicine, facilitated by the progress in ‐omics technologies, has initiated a new era in medical diagnostics and treatment. This review examines the potential of ‐omics approaches in heart failure, a condition that has not yet fully capitalized on personalized strategies compared to other medical fields like cancer therapy. Here, we argue that integrating multi‐omics technology with systems medicine approaches could fundamentally transform heart failure management, moving away from the traditional paradigm of ‘one size fits all’. Our review examines how omics can enhance understanding of heart failure's molecular foundations and contribute to a more comprehensive disease classification. We draw attention to the current state of medical practice that only relies on clinical evidence and a number of standard laboratory tests. At the same time, we propose a shift towards a universal approach that uses quantitative data from multi‐omics to unravel complex molecular interactions. The discussion centres around the potential of the transition as a means to enhance individual risk assessment and emphasizes management within clinical settings. While the use of omics in cardiovascular research is not recent, many past studies have focused only on a single omics approach. In order to achieve a better understanding of disease mechanisms, we explore more holistic approaches using genomics, transcriptomics, epigenomics, and proteomics. This review concludes with a call to action to adopt multi‐omics in clinical trials and practice to pave the way for more personalized disease management and more effective heart failure interventions.